RecruitingNot ApplicableNCT06742021
Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
Sponsor
Yunnan Cancer Hospital
Enrollment
195 participants
Start Date
Nov 11, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. By utilizing two DCE-MRI images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria2
- Tumor size greater than 2 cm
- Age between 18 and 75 years
Exclusion Criteria3
- Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.)
- Allergy to gadolinium contrast agents
- Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions
Interventions
DIAGNOSTIC_TESTApplication Value of MRI Imaging in Treatment Decision-Making for Lung Cancer
Chest MRI scans outside of the standard treatment protocol
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06742021
Related Trials
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Empathic Communication Skills (ECS) Training
NCT0545684112 locations
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667100 locations
Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block
NCT066185991 location